Ocular Therapeutix stock moves

Ocular Therapeutix (OCUL) has been drawing attention after a stretch of weak share performance, with the stock down 6.3% on the day and declining over the past week, month, and past 3 months.

That weak one day share price move sits on top of a fading trend, with the 30 day share price return down 14.51%, the year to date share price return down 30.20%, and the 1 year total shareholder return down 8.54%, even though the 3 year total shareholder return is positive at 11.04%.

If you are weighing OCUL against other healthcare ideas, this could be a good moment to widen the net and scan for 39 healthcare AI stocks

With OCUL trading at $8.25 and carrying a value score of 2, yet sitting at a large discount to a US$26 price target and an intrinsic discount of 91.08%, is there a genuine opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 68.3% Undervalued

At $8.25 a share versus a narrative fair value of $26, the gap on Ocular Therapeutix is wide, and the current focus sits squarely on its retinal franchise.

The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6 to 12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.

Curious what underpins that $26 figure? The narrative leans on rapid revenue expansion, a sharp swing in profit margins and a future earnings multiple more often seen in high growth sectors.

Result: Fair Value of $26 (UNDERVALUED)

However, this upbeat story leans heavily on AXPAXLI. Any clinical or regulatory setback, or slower than expected physician adoption, could quickly challenge that $26 narrative.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Rich Sales Multiple Raises the Bar

That $26 fair value from the narrative leans heavily on future cash flows, but today the market is already paying a very high price for OCUL's current sales. The stock trades on a P/S of 34.7x, compared with 5.8x for the US pharmaceuticals industry and 5.5x for peers, while the fair ratio is just 0.1x. For investors, the question is whether future growth can close such a wide gap or if the multiple itself becomes the main risk.

Before relying on any single approach, it can help to see what the numbers imply when this sales ratio is pushed back toward a fair ratio in our valuation work. You can review this in more detail in the See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

With sentiment clearly mixed after all this, it makes sense to move fast, review the full picture yourself and weigh both sides using the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

OCUL may be on your radar, but the market is full of other opportunities, so do not miss the chance to line up your next moves.

• Spot potential value plays early by scanning 49 high quality undervalued stocks before other investors pay attention.
• Prioritise resilience and sleep easier at night by focusing on 61 resilient stocks with low risk scores that score well on stability.
• Act on underfollowed opportunities by running the screener containing 21 high quality undiscovered gems and seeing which solid fundamentals the crowd is overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.